A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03398148 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

1558

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis (UC)

Interventions

DRUG: risankizumab IV
DRUG: placebo for risankizumab
DRUG: risankizumab SC

Sponsor

AbbVie